Immunic
IMUX
42 hedge funds and large institutions have $51.7M invested in Immunic in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 14 closing their positions.
65% more capital invested
Capital invested by funds: $31.3M → $51.7M (+$20.4M)
0% less ownership
Funds ownership: 0.06% → 0.06% (-0%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
16% less funds holding
Funds holding: 50 → 42 (-8)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
93% less call options, than puts
Call options by funds: $8K | Put options by funds: $115K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$582K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$431K |
| 3 |
Renaissance Technologies
New York
|
+$177K |
| 4 |
DY
Dowling & Yahnke
San Diego,
California
|
+$163K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$719K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$545K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$396K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$347K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$301K |
IMUX Hedge Fund Activity: Q3 2017 in Review
42 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q3 2017, worth a combined $51.7M — up 65% from $31.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IMUX and 7 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $582K. The largest seller was Goldman Sachs, cutting an estimated $719K.
- 42 institutional investors held Immunic (IMUX) as of Q3 2017, down from 50 in Q2 2017.
- Funds reported $51.7M of Immunic stock for Q3 2017, up 65% quarter-over-quarter.
- 7 funds opened new Immunic positions in Q3 2017 and 14 closed out, a net change of -7 holders.
- The largest Immunic buyer in Q3 2017 was Vanguard Group, an estimated $582K added.
- The largest Immunic seller in Q3 2017 was Goldman Sachs, an estimated $719K sold.
Based on aggregated 13F filings for Q3 2017.